Casdin Capital 13F holdings, Q2 2017
Holdings as of June 30, 2017 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 31 US equity positions worth $250.0m in its Q2 2017 13F filing. The largest position was LOXO ONCOLOGY INC at 11.5% of the reported book, followed by SG7 and FOUNDATION MEDICINE INC. Against the Q1 2017 filing, it opened 5 new positions, added to 16 and reduced 3 among the top 31 holdings.
What did Casdin Capital own in Q2 2017? Top 31 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2017 |
|---|---|---|---|---|---|---|---|
| 1 | LOXO ONCOLOGY INC | 11.5% | $28.9m | 360,000 | 0% | held | |
| 2 | SG7 SAGE THERAPEUTICS INC | 8.1% | $20.3m | 255,000 | 0% | held | |
| 3 | FOUNDATION MEDICINE INC | 7.6% | $19.1m | 480,000 | 0% | held | |
| 4 | 2655787D BLUEPRINT MEDICINES CORP | 5.6% | $13.9m | 275,000 | -7% | reduced | |
| 5 | EVH EVOLENT HEALTH INC | Healthcare | 5.3% | $13.2m | 520,000 | 0% | held |
| 6 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 5.2% | $13.1m | 255,000 | 7% | added |
| 7 | SGMOQ SANGAMO THERAPEUTICS INC | Healthcare | 4.9% | $12.3m | 1,400,000 | 65% | added |
| 8 | CLOVIS ONCOLOGY INC | 4.9% | $12.2m | 130,000 | 465% | added | |
| 9 | SPARK THERAPEUTICS INC | 4.1% | $10.2m | 170,000 | 26% | added | |
| 10 | KITE PHARMA INC | 3.7% | $9.3m | 90,000 | 112% | added | |
| 11 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 3.3% | $8.4m | 105,000 | 91% | added |
| 12 | GNMK GENMARK DIAGNOSTICS INC | 3.2% | $8.1m | 685,000 | 71% | added | |
| 13 | EPIZYME INC | 3.1% | $7.9m | 520,000 | 7% | added | |
| 14 | AUDENTES THERAPEUTICS INC | 3.1% | $7.7m | 400,000 | 54% | added | |
| 15 | BLUEBIRD BIO INC | 2.7% | $6.8m | 65,000 | 155% | added | |
| 16 | T8S TESARO INC | 2.7% | $6.7m | 48,000 | 174% | added | |
| 17 | VYGR VOYAGER THERAPEUTICS INC | Healthcare | 2.7% | $6.6m | 740,000 | 48% | added |
| 18 | CDXS CODEXIS INC | Healthcare | 2.6% | $6.5m | 1,190,000 | 76% | added |
| 19 | GLOBAL BLOOD THERAPEUTICS IN | 2.4% | $5.9m | 215,000 | 112% | added | |
| 20 | ILMN ILLUMINA INC | Healthcare | 2.2% | $5.5m | 31,500 | – | new |
| 21 | GILD GILEAD SCIENCES INC | Healthcare | 2.1% | $5.3m | 75,000 | – | new |
| 22 | MYOKARDIA INC | 2.1% | $5.2m | 395,000 | 49% | added | |
| 23 | SYROS PHARMACEUTICALS INC | 1.2% | $2.9m | 182,141 | 0% | held | |
| 24 | CTMX CYTOMX THERAPEUTICS INC | Healthcare | 1.1% | $2.8m | 177,500 | 0% | held |
| 25 | OVID OVID THERAPEUTICS INC | Healthcare | 0.9% | $2.3m | 221,700 | – | new |
| 26 | JOUNCE THERAPEUTICS INC | 0.9% | $2.2m | 160,000 | 23% | added | |
| 27 | EDIT EDITAS MEDICINE INC | Healthcare | 0.9% | $2.2m | 133,333 | 0% | held |
| 28 | FATE FATE THERAPEUTICS INC | Healthcare | 0.7% | $1.8m | 550,000 | – | new |
| 29 | AMYRIS INC | 0.6% | $1.6m | 500,000 | – | new | |
| 30 | PACB PACIFIC BIOSCIENCES CALIF IN | Healthcare | 0.4% | $1.1m | 300,000 | -57% | reduced |
| 31 | CRIS CURIS INC | 0.1% | $161.0k | 85,000 | -63% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.